1-3 of 3
Romeo Mandanas
Close
Sort by
Journal Articles

Use of Rituximab in a Study Comparing the Thrombopoietin Mimetic Romiplostim with Standard of Care (SOC) in Patients with Immune Thrombocytopenia (ITP),

Jeffrey Wasser, MD, Ralph Vincent V. Boccia, MD, Roger M. Lyons, MD, Romeo Mandanas, Ingrid Pabinger, Marc Michel IV, Jean-François Viallard, MD-PhD, Xuena Wang, PhD, Richard Lizambri, MD
Journal: Blood
Blood (2011) 118 (21): 3282.
https://doi.org/10.1182/blood.V118.21.3282.3282
Published: 2011
Journal Articles

Patient Quality of Life (QOL) In Nonsplenectomized Immune Thrombocytopenia (ITP) Patients Receiving Romiplostim or Medical Standard of Care (SOC)

Mathias J. Rummel, MD, PhD, David J. Kuter, MD, DPhil, Romeo Mandanas, MD, Aristoteles Giagounidis, MD, Xuena Wang, PhD, Susan D. Mathias, MPH, Robert Deuson, PhD
Journal: Blood
Blood (2010) 116 (21): 569.
https://doi.org/10.1182/blood.V116.21.569.569
Published: 2010
Journal Articles

Results of a Randomized Phase II Trial of Pegfilgrastim Versus Filgrastim To Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin’s Lymphoma (NHL).

Robert Rifkin, MD, Roy Beveridge, MD, Gary Spitzer, MD, Gregory Orloff, MD, Romeo Mandanas, MD, Dean McGaughey, MD, Mark Brunvand, MD, Feng Zhan, PhD, Kristi A. Boehm, MS, Lina Asmar, PhD
Journal: Blood
Blood (2007) 110 (11): 4936.
https://doi.org/10.1182/blood.V110.11.4936.4936
Published: 2007